Cryptyx Bioscience

Cryptyx Bioscience is a private Princeton, New Jersey biotechnology company developing therapeutics from cryptic microbial metabolites. Its core HiTES platform is a high-throughput, genetics-free and cloning-free discovery system designed to activate silent biosynthetic gene clusters in bacteria and reveal novel natural-product drug leads. The company is focused primarily on infectious disease, including drug-resistant bacterial pathogens and respiratory syncytial virus, and has stated that it is expanding research into oncology. In addition to advancing its own preclinical pipeline, Cryptyx offers platform-enabled services and licenses intellectual property covering novel microbial metabolites. The company appears to be an early-stage platform biotech built around natural-product discovery and lead generation rather than clinical-stage development.